Therapeutic potential of elafin in airway inflammatory disease

Authors:

Abstract
Elafin, which is derived from trappin-2 or pre-elafin by proteolysis, is an endogenous serine protease inhibitor with a low molecular weight. Its inhibitory activity is dependent on anchoring to the extracellular matrix by forming covalent bonds with its distinctive N-terminal domain via tissue transglutaminases. In addition to inhibiting proteases, it also exhibits anti-inflammatory, antibiotic, antifungal, antiviral and immunomodulatory functions. Elafin plays an important role in inflammatory disease and is a promising candidate for the anti-inflammatory treatment of respiratory diseases. This review will discuss the therapeutic potential of elafin in airway inflammation and provide evidence and suggestions for the future treatment of airway inflammatory diseases. In addition, the therapeutic potential of elafin in lung cancer is also discussed.
Funding Information
  • NHC Key Laboratory of Tropical Disease Control, Hainan Medical University (2021NHCTDCKFKT21008)
  • National Natural Science Foundation of China (82260001, 81860001, 82160012)
  • Hainan Provincial Science and Technology Major Project (ZDKJ2021036, ZDKJ202004, ZDKJ2021038)
  • Province Innovation Team Project of Hainan (820CXTD448)
  • Hainan Province Key R&D Program International Science and Technology Cooperation Project (GHYF2022011)
  • Key R&D Projects in Hainan Provinc (ZDYF2020223)
  • Hainan Provincial Clinical Medical Center Construction Project Fund
  • Chinese Academy of Medical Sciences Medical and Health Science and Technology Innovation Engineering Project (2019-12M-5-023)
  • Hainan Provincial Natural Science Foundation of China (822MS071)

This publication has 69 references indexed in Scilit: